Caris Q3 Net Income Declines 37% Despite 27% Revenue Growth; Raises FY26 Outlook

Caris Life Sciences (CAI) reported Q3 2026 net income down 37% YoY to $15.3M, despite 27% revenue growth to $275.4M. Operating expenses rose 42%, and adjusted EBITDA fell. The company raised FY26 revenue guidance to $1.04B-$1.05B, citing higher clinical case volumes and improved pricing. CAI shares were up 1.13% at close but fell 11.71% in overnight trading.

Original reporting
Published Nov 5, 2026, 7:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CAI
Bearish
high confidence
Mentioned
$CAI
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CAIBearishHigh
01

Why it matters

The earnings miss triggered an 11.7% after‑hours drop, yet the raised guidance may cushion further downside.

02

Market read

First‑time earnings release with new guidance; material for biotech traders.

03

What to watch

Cash position of $767M provides runway for R&D and potential acquisitions.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Caris Life Sciences reported Q3 2026 results with a profit decline but strong revenue growth and raised full‑year guidance.

Company-level read

Ticker impact

$CAIBearishHigh confidence
Context

Q3 net income fell 37% to $15.3M while revenue rose 27% to $275.4M; company raised FY2026 revenue guidance to $1.04‑$1.05B.

Expected impact

likely pressure as investors weigh profit decline against revenue growth and higher guidance

Evidence & confidence

The sharp drop in net income and after‑hours share decline suggest downside, but the raised revenue outlook may limit the sell‑off.

Market effects

Highlights growing demand for molecular profiling, may benefit peers in precision‑medicine space.

U.S. biotech sector could see modest volatility as investors reassess earnings quality.

Limited to biotech investors; no broad macro impact.

Counterpoint

Revenue acceleration and higher guidance could outweigh profit dip, supporting a bounce.

Key entities

  • Caris Life Sciences, Inc.

    TechBio firm focused on precision medicine and molecular profiling.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.

$CAIMed

Caris Life Sciences Q3 Earnings Call Highlights

Caris Life Sciences reported Q3 net income of $15.3M, down from $24.3M YoY, with adjusted EBITDA at $44.4M. Operating expenses rose to $163M, and full-year expense forecast increased to $620M. Free cash flow was negative $39.7M. The company launched new cancer-detection tests and plans to introduce them selectively. Caris Detect, a multi-cancer early detection test, is being marketed with campaigns and partnerships. The company has 325 commercial team members and plans to expand further.